An interventional study of Weekly group training in Migraine, Headache Disorders and Pediatric Migraine, sponsored by Medical University Innsbruck. Completed at 1 site in Austria. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Medical University Innsbruck · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Migraine Disorders with a site in Austria — 4 open to participants now, 6 under way, 2 of them phase 3. Migraine Disorders · Austria.
Among the 20 studies in Migraine Disorders with a site in Austria, this one is the 16th largest by enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2025, is one of 3 with no phase, and was the 20th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →4 of the 20 studies in Migraine Disorders with a site in Austria are open now. Recruiting first, the newest first:
Brightmind.AI · Sites in Austria
Ages 18–65
Austrian Migraine Registry Collaboration · Sites in Austria
Ages 18+
Medical University of Vienna · Sites in Austria
Ages 18–64 · Healthy volunteers
Bernhard Taxer · Sites in Austria
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 12 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 621 across the 17 interventional studies, 120 across the 3 observational. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 10 most frequent:
Medical University Innsbruck is the lead sponsor of 187 studies on the registry; 48 are open to participants now.
Medical University Innsbruck has 2 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Migraine Disorders with a site in Austria that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Migraine Disorders with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background: The prevalence of migraine during adolescence is 7.7%, affecting 9.7% of girls and 6.0% of boys. Despite its high prevalence, treatment options remain limited. Insufficient treatment may increase the risk of headache chronification or the development of medication-overuse headache. In Tyrol, 21.7% of children and adolescents with chronic headache exhibit medication overuse.
To improve the care of adolescents with migraine, a regularly scheduled, professionally supervised group intervention could be of considerable value. Physical exercise and relaxation techniques are already recommended in guidelines for migraine management. Although there is a substantial body of evidence regarding the effectiveness of these non-pharmacological preventive approaches in adults, findings remain heterogeneous, making it difficult to reliably estimate their true effect. Evidence in children and adolescents is still scarce.
Methods: We hypothesize that a combination of high-intensity interval training (HIIT) and progressive muscle relaxation (PMR) may provide a particularly effective non-pharmacological preventive approach. In addition, the psychosocial benefits of exercising together represent an important component of the intervention, which is therefore delivered in a group setting.
Although patients are routinely advised during medical consultations to increase their level of physical activity, implementing this recommendation in everyday life can be challenging for many adolescents. A supervised, on-site group intervention may help increase motivation and adherence.
Discussion: If the intervention results in a significant reduction in migraine attack frequency and migraine-related burden, the findings could provide a basis for securing financial support to establish the program as a long-term extension of care for adolescents with migraine. Such an intervention could sustainably reduce the burden of migraine and may therefore be of considerable relevance to real-world clinical care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behavioral: Weekly group training Weekly high-intensity interval training followed by progressive muscle relaxation in a group setting, plus two additional psychoeducation sessions focusing on pain management
Behavioral: Weekly group training
Weekly high-intensity interval training followed by progressive muscle relaxation in a group setting, plus two additional psychoeducation sessions focusing on pain management
Mean change from baseline in migraine headache frequency
Mean change from baseline in the number of monthly headache days, defined as any calendar day with headache
Time frame: From enrollment to the end of treatment at 4 weeks
Mean change from baseline in migraine intensity
Mean change from baseline in migraine intensity measured using a 0-10 visual analogue scale (VAS), where 0 indicates no pain and 10 indicates worst imaginable pain
Time frame: From enrollment to the end of treatment at 4 weeks
Mean change from baseline in migraine duration
Mean change from baseline in the duration of migraine, expressed as the number of hours of pain per migraine day
Time frame: From enrollment to the end of treatment at 4 weeks
Degree of migraine-related impairment using the mean change in the PedMIDAS questionnaire´s total score
Migraine-related disability was assessed using the Pediatric Migraine Disability Assessment (PedMIDAS) questionnaire (total score range: 0-276). Higher scores indicate greater migraine-related disability (worse outcome). The outcome parameter was the mean change from baseline in the PedMIDAS total score.
Time frame: From enrollment to the end of treatment at 4 weeks
Plan to share: No — This is a single-center study without the need of sharing IPD with other researchers.
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in Sep 2025, 7 months.
Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 7 months is below that.
Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University Innsbruck →